Previous 10 | Next 10 |
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease, announced today that management will...
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease, today announced that the Company wil...
Summary The Clinical Trials on Alzheimer’s Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen. This conference...
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that it published its development rationale and clinical development plan for ACU193, the first clinical-stage monoclonal antibody that selectively target...
Acumen Pharmaceuticals ( NASDAQ: ABOS ) said on Monday its monoclonal antibody, ACU193, that targets toxic soluble amyloid beta oligomers to treat early Alzheimer’s disease has been granted fast track designation by the U.S. Food and Drug A...
CHARLOTTESVILLE, Va. and CARMEL, Ind., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs), has been granted Fa...
Summary Acumen has ACU193, an anti-amyloid oligomer antibody and its only drug candidate, in a Phase 1 trial. The Eisai news on lecanemab led to Acumen’s share price more than doubling. ACU193's mechanism of action builds on scientific publications identifying amyloid o...
The shares of microcap biotech Acumen Pharmaceuticals, Inc. ( NASDAQ: ABOS ) more than doubled in value on Wednesday after its rivals Biogen ( BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESALY ) announced promising late-stage data for experimental Alzheimer's therapy,...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Atthapon Raksthaput / Shutterstock.com Prothena (NASDAQ: PRTA ) stock is seeing massive gains on Wednesday despite a lack of news from the late-stage clinical company. However, there is news from Biog...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: pathdoc / Shutterstock.com Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is rocketing higher on Wednesday but it’s not due to any news from the company. Instead, investors have Biogen (NAS...
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer’s disease (AD),&...
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...